{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:19:22Z","timestamp":1793035162027,"version":"4.5.0"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"\n Background<\/jats:title>\n Atopic dermatitis (AD) is a chronic, recurrent, inflammatory skin disease. Although dupilumab has demonstrated favorable efficacy in the treatment of patients with moderate-to-severe atopic dermatitis, data on its recurrence after discontinuation remain limited.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To explore the recurrence rate, time to recurrence, and factors influencing recurrence in patients with moderate-to-severe AD after discontinuing dupilumab, to bridge the existing knowledge gap and provide a reference for promoting long-term standardized management of the disease in AD patients to reduce AD recurrence.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Patients with moderate-to-severe AD treated with dupilumab between January 2021 and December 2023 at Sichuan Provincial People\u2019s Hospital were included. All patients started from the time of drug discontinuation, and baseline characteristics of patients were collected from all enrolled patients, and follow-up visits were conducted every 2\u202fweeks after drug discontinuation utilizing telephone or medical records. Descriptive statistics summarized the relapse rate and time to relapse, and the Cox proportional hazards model was applied to determine the predictive factors of relapse after discontinuing dupilumab.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n By the follow-up cut-off time, the median follow-up time was 49\u202fweeks (24\u201385\u202fweeks), and 141\u202fAD patients were finally included in the statistical analysis. Of the 141 patients, 33 patients relapsed, with a relapse rate of 23.4% (95% CI, 16\u201330%), and the median time to relapse was 29\u202fweeks. Predictors with a significant effect on recurrence included allergic conjunctivitis (HR\u202f=\u202f7.912, 95% CI, 1.280\u201348.895,\n p<\/jats:italic>\n \u202f=\u202f0.026), duration of treatment &lt;16\u202fweeks (HR\u202f=\u202f5.871, 95% CI, 2.154\u201316.003,\n p<\/jats:italic>\n \u202f=\u202f0.001), BMI\u202f\u2265\u202f28 (HR\u202f=\u202f5.653, 95% CI, 2.331\u201313.713,\n p<\/jats:italic>\n \u202f&lt;\u202f0.001), male (HR\u202f=\u202f5.634, 95% CI, 1.727\u201318.373,\n p<\/jats:italic>\n \u202f=\u202f0.004), and positive familial predisposition to allergy (HR\u202f=\u202f3.438, 95% CI, 1.351\u20138.747,\n p<\/jats:italic>\n \u202f=\u202f0.01).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n The cumulative recurrence rate in 141\u202fAD patients was 23.4%; the median time to recurrence in 33\u202fAD recurrence patients was 29\u202fweeks (22\u201359\u202fweeks); comorbid allergic conjunctivitis, treatment duration shorter than 16\u202fweeks, obesity, male patients, and positive familial predisposition to allergy were independent risk factors for AD recurrence. These findings confirm the disease characteristic of AD\u2019s susceptibility to relapse and emphasize the need for individualized treatment, post-discontinuation monitoring, and long-term standardized management of AD patients with different risk factors for relapse.<\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fmed.2025.1585368","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T04:15:47Z","timestamp":1755058547000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Recurrence and influencing factors of moderate-to-severe atopic dermatitis after dupilumab withdrawal: a retrospective cohort analysis"],"prefix":"10.3389","volume":"12","author":[{"given":"Maohua","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ge","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingqing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyuan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinjie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,13]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/S0140-6736(06)69283-0","article-title":"Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC phases one and three repeat multicountry cross-sectional surveys","volume":"368","author":"Asher","year":"2006","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.3346\/jkms.2017.32.8.1360","article-title":"Clinical features of atopic dermatitis in adults are different according to onset","volume":"32","author":"Son","year":"2017","journal-title":"J Korean Med Sci"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"222[EB\/OL]","DOI":"10.3390\/antibiotics12020222","article-title":"Staphylococcus infection: relapsing atopic dermatitis and microbial restoration","volume":"12","author":"Hulme","year":"2023","journal-title":"Antibiotics"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"4130","DOI":"10.3390\/ijms22084130","article-title":"Molecular mechanisms of atopic dermatitis pathogenesis","volume":"22","author":"Sroka-Tomaszewska","year":"2021","journal-title":"Int J Mol Sci"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1159\/000530608","article-title":"Dupilumab-associated psoriasis and psoriasiform manifestations: a scoping review","volume":"239","author":"Su","year":"2023","journal-title":"Dermatology"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"S118","DOI":"10.1016\/j.jaci.2003.09.033","article-title":"Atopic dermatitis and the atopic march","volume":"112","author":"Spergel","year":"2003","journal-title":"J Allergy Clin Immunol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s13555-021-00505-z","article-title":"Efficacy and safety of dupilumab in clinical practice: one year of experience on 165 adult patients from a tertiary referral Centre","volume":"11","author":"Napolitano","year":"2021","journal-title":"Dermatol Ther"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"371","author":"Beck","year":"2014","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1111\/jdv.18932","article-title":"Multicenter prospective observational study of dupilumab-induced ocular events in atopic dermatitis patients","volume":"37","author":"Costedoat","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.anai.2018.07.006","article-title":"Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study","volume":"121","author":"Silverberg","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"15990","DOI":"10.1038\/s41598-019-51129-5","article-title":"Factors influencing quality of life in children with atopic dermatitis and their caregivers: a cross-sectional study","volume":"9","author":"Xu","year":"2019","journal-title":"Sci Rep"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jid.2016.07.012","article-title":"The burden of atopic dermatitis: summary of a report for the National Eczema Association","volume":"137","author":"Drucker","year":"2017","journal-title":"J Invest Dermatol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"855","DOI":"10.13735\/j.cjdv.1001-7089.202205115","article-title":"Expert Guidance and Recommendations on Systemic Medication for Targeted Treatment of Moderate to Severe Atopic Dermatitis","volume":"36","author":"Zuotao","year":"2022","journal-title":"Chin J Dermatol Venereol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.5415\/apallergy.2018.8.e41","article-title":"A clinician\u2019s reference guide for the management of atopic dermatitis in Asians","volume":"8","author":"Chow","year":"2018","journal-title":"Asia Pac Allergy"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1111\/jdv.16892","article-title":"ETFAD\/EADV eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children","volume":"34","author":"Wollenberg","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1089\/derm.2024.0014","article-title":"Efficacy, safety, and early relapse after cessation of Upadacitinib versus Dupilumab in adolescents with moderate-to-severe atopic dermatitis: a real-world study in China","volume":"35","author":"Zhu","year":"2024","journal-title":"Dermatitis"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1016\/j.jaip.2018.01.034","article-title":"Conjunctivitis occurring in atopic dermatitis patients treated with dupilumab\u2013clinical characteristics and treatment","volume":"6","author":"Wollenberg","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.jaci.2019.01.003","article-title":"Report from the National Institute of Allergy and Infectious Diseases workshop on \u201catopic dermatitis and the atopic march: mechanisms and interventions\u201d","volume":"143","author":"Davidson","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.jaci.2015.06.045","article-title":"Spontaneous atopic dermatitis is mediated by innate immunity, with the secondary lung inflammation of the atopic march requiring adaptive immunity","volume":"137","author":"Saunders","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.jaci.2019.09.031","article-title":"Evolution of pathologic T-cell subsets in patients with atopic dermatitis from infancy to adulthood","volume":"145","author":"Czarnowicki","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/s41573-023-00735-0","article-title":"Disease modification in inflammatory skin disorders: opportunities and challenges","volume":"22","author":"Bieber","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/j.jaci.2010.12.1124","article-title":"Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities","volume":"127","author":"Su\u00e1rez-Fari\u00f1as","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1111\/all.13223","article-title":"Nonlesional atopic dermatitis skin shares similar T-cell clones with lesional tissues","volume":"72","author":"Brunner","year":"2017","journal-title":"Allergy"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"eaav 2685","DOI":"10.1126\/scitranslmed.aav2685","article-title":"The nonlesional skin surface distinguishes atopic dermatitis with food allergy as a unique endotype","volume":"11","author":"Leung","year":"2019","journal-title":"Sci Transl Med"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/all.14490","article-title":"Tape strips from early-onset pediatric atopic dermatitis highlight disease abnormalities in nonlesional skin","volume":"76","author":"Pavel","year":"2021","journal-title":"Allergy"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"3445","DOI":"10.1111\/all.15423","article-title":"Tape strips capture atopic dermatitis-related changes in nonlesional skin throughout maturation","volume":"77","author":"Renert-Yuval","year":"2022","journal-title":"Allergy"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1111\/jdv.18345","article-title":"European guideline (euro Gui Derm) on atopic eczema: part I\u2013systemic therapy","volume":"36","author":"Wollenberg","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/j.jaad.2020.06.054","article-title":"Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial","volume":"83","author":"Paller","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1111\/jdv.18109","article-title":"Real-world efficacy and safety of dupilumab in Chinese patients with atopic dermatitis: a single-Centre, prospective, open-label study","volume":"36","author":"Gu","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s40257-022-00683-2","article-title":"Long-term efficacy and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis: results through week 52 from a phase III open-label extension trial (LIBERTY AD PED-OLE)","volume":"23","author":"Blauvelt","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1111\/jdv.18378","article-title":"Factors associated with severity of atopic dermatitis\u2013a Finnish cross-sectional study","volume":"36","author":"Salava","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s00403-019-01895-z","article-title":"Determinants of disease severity among patients with atopic dermatitis: association with components of the atopic march","volume":"311","author":"Holm","year":"2019","journal-title":"Arch Dermatol Res"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1111\/jdv.18141","article-title":"Moderate-to-severe atopic dermatitis in adolescents treated with dupilumab: a multicentre Italian real-world experience","volume":"36","author":"Stingeni","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1080\/14712598.2024.2372367","article-title":"Predisposition to conjunctivitis and male sex reduces drug survival of dupilumab in adults and adolescents","volume":"24","author":"Mastorino","year":"2024","journal-title":"Expert Opin Biol Ther"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/jdv.20042","article-title":"Obesity is linked to disease severity in moderate to severe atopic dermatitis\u2014data from the prospective observational TREATgermany registry","volume":"39","author":"Traidl","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.1111\/jdv.20111","article-title":"The impact of body mass index on dupilumab treatment outcomes in adult atopic dermatitis patients","volume":"39","author":"Patruno","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1002\/cpdd.780","article-title":"Base and covariate population pharmacokinetic analyses of dupilumab using phase 3 data","volume":"9","author":"Kovalenko","year":"2020","journal-title":"Clin Pharmacol Drug Dev"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/s41586-022-04536-0","article-title":"Obesity alters pathology and treatment response in inflammatory disease","volume":"604","author":"Bapat","year":"2022","journal-title":"Nature"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1089\/derm.2024.0160","article-title":"Early dupilumab response predicts pediatric atopic dermatitis disease relapse","author":"Zhao","year":"2024","journal-title":"Dermatitis"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1093\/bjd\/ljae278","article-title":"Predictive features for effectiveness of dupilumab in elderly patients with atopic dermatitis: a real-world study","volume":"191","author":"Jia","year":"2024","journal-title":"Br J Dermatol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S0140-6736(22)01199-0","article-title":"Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial","volume":"400","author":"Reich","year":"2022","journal-title":"Lancet"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1111\/1346-8138.16176","article-title":"Atopic dermatitis control tool (ADCT): a useful tool for self-evaluation in patients with atopic dermatitis","volume":"48","author":"Kido-Nakahara","year":"2021","journal-title":"J Dermatol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.35541\/cjd.20240321","article-title":"Expert consensus on stratified and individualized systematic treatment for moderate to severe atopic dermatitis","volume":"57","year":"2024","journal-title":"Chin J Dermatol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1585368\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T04:15:48Z","timestamp":1755058548000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1585368\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,13]]},"references-count":44,"alternative-id":["10.3389\/fmed.2025.1585368"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1585368","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,13]]},"article-number":"1585368"}}